GLSI - קצב צמיחת הכנסות משנה לשנה ב-12 החודשים האחרונים Greenwich LifeSciences

The prospects for Greenwich LifeSciences (GLSI) depend on the results of the final testing phase of the vaccine against breast cancer recurrence and FDA approval. The rolling annual sales growth metric illustrates revenue dynamics, where 0.00 reflects the current volume of the indicator. Efficiency is increasing through cloud automation of clinical data processing, and the expected results of GP2 therapy are already priced in.
פילוחי נתונים אנליטיים מרוכזים עבור Greenwich LifeSciences, Inc (GLSI)

This indicator measures the percentage change in aggregate revenue over the last 12 months relative to the same period last year, allowing for the identification of demand pivot points prior to official reports. For Greenwich LifeSciences (GLSI), this metric reflects the impact of geopolitical sanctions and logistical disruptions on drug commercialization rates, which is clearly demonstrated by the relative year-over-year (12-month) revenue growth rate.